ADC Therapeutics (ADCT) Q2 2026 Earnings Call Transcript

ADC Therapeutics reported Q2 2026 net product revenue of $18.6M (up from $18.1M YoY) alongside improved profitability metrics: GAAP net loss narrowed to $16.6M from $56.6M, helped by a 22% YoY decline in adjusted operating expenses ($37.2M) and a 17% workforce reduction expected to generate ~$10M in annualized cost savings. The key overhang is regulatory: the FDA flagged “substantial concerns” on the ZYNLONTA plus rituximab LOTIS-5 combination during a pre-sBLA meeting, leaving the company assessing risk-management or label modifications, while it simultaneously plans breakthrough designation and potential Phase III evaluation for the ZYNLONTA + glofitamab LOTIS-7 program. Liquidity also remains a positive: cash and cash equivalents were $219.1M, expected to fund operations into 2028, though interest expense rose slightly to $13.5M.

Analysis

The key read is not the quarter; it is that the equity now trades on regulatory optionality rather than operating performance. Monotherapy looks like a stable cash generator, but the valuation gap is being driven by whether the company can convert a niche approved product into a second-line franchise; FDA skepticism turns that from a near-term execution story into a potentially multi-quarter gap risk. Cash runway into 2028 lowers dilution risk, so the downside is more about multiple compression than solvency, but that also means the stock can stay cheap for longer if the approval path remains opaque.

Competitive dynamics matter because lymphoma physicians are already conditioned to move toward the cleanest efficacy/safety package, and a delayed or messy path for the combination hands share to better-established bispecific and cellular-therapy ecosystems. The market may be underestimating how much compendia adoption and reimbursement depend on a cleaner, easier-to-defend package than a single positive endpoint with unresolved safety questions. If the combination is forced into a new randomized study, the revenue inflection likely shifts from 2027 to 2028+.

The contrarian point is that the negative reaction may be less about terminal risk than about timing risk: the single-agent business is likely insulated, and the company is not facing an immediate balance-sheet problem. That argues against an aggressive structural short. The cleaner expression is to fade optimism into catalyst windows, because any upside now depends on ASH data and FDA follow-up landing better than expected; absent that, the stock is likely to remain range-bound with a downward bias.

Key Decisions for Investors

• Tactically short ADCT on any post-call rally or buy 3-6 month put spreads; the catalyst risk is asymmetric because the market is now waiting for regulatory clarity rather than revenue acceleration. Risk/reward is favorable if the next update implies a new trial or label constraints.
• Do not short ADCT as a solvency trade. The cash runway into 2028 argues the bear case is multiple compression, not imminent dilution; cover quickly if management secures FDA alignment or breakthrough designation.
• Relative-value: short ADCT vs long XBI as a beta-neutral expression of company-specific regulatory risk. This isolates the FDA overhang while reducing exposure to sector-wide biotech sentiment.
• If already long ADCT, trim into strength and wait for either ASH readout or a clearly defined Phase III/regulatory pathway before re-adding. The thesis is not broken, but the timing premium has been removed.